Board of Regents, The University of Texas System;The Government of the United States of America, As Represented by the Secretary, Department of Healt;Amgen Inc.
发明人:
Alexander M. DePaoli,Elif A. Oral,Simeon I. Taylor,Abhimanyu Garg
申请号：
US16195661
公开号：
US20190321447A1
申请日:
2018.11.19
申请国别(地区):
US
年份:
2019
代理人:
摘要：
Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
